| Literature DB >> 32449044 |
Carlo Luca Romanò1,2, Lorenzo Drago3, Hernán Del Sel4, Ashok Johari5, Guenter Lob6, Andreas F Mavrogenis7, Thami Benzakour8.
Abstract
The media play a key role in promoting public health and influencing debate regarding health issues; however, some topics seem to generate a stronger response in the public, and this may be related to how the media construct and deliver their messages. Mass media coverage of COVID-19 epidemic has been exceptional with more than 180,000 articles published each day in 70 languages from March 8 to April 8, 2020. One may well wonder if this massive media attention ever happened in the past and if it has been finally proven to be beneficial or even just appropriate. Surgical site and implant-related infections represent a substantial part of health care-associated infections; with an estimated overall incidence of 6% post-surgical infection, approximately 18 million new surgical site infections are expected each year globally, with 5 to 10% mortality rate and an astounding economic and social cost. In the current mediatic era, orthopaedic surgeons need to refocus some of their time and energies from surgery to communication and constructive research. Only raising mediatic awareness on surgical site and implant-related infections may tune up the volume of silent epidemics to a level that can become audible by governing institutions.Entities:
Keywords: COVID-19; Mass-media; Mortality; Orthopaedics; Periprosthetic joint infections; Surgical site infections; Tuberculosis
Mesh:
Year: 2020 PMID: 32449044 PMCID: PMC7246223 DOI: 10.1007/s00264-020-04608-8
Source DB: PubMed Journal: Int Orthop ISSN: 0341-2695 Impact factor: 3.075
Impact of various infectious conditions
| COVID-19 [ | Tuberculosis [ | Seasonal flu (Influenza) [ | Swine flu [ | AIDS [ | Hepatitis C [ | Health-care-associated infections [ | Implant-related infections [ | |
|---|---|---|---|---|---|---|---|---|
| Pathogen | SARS-COV-2 | Mycobacterium spp. | Influenza viruses A, B, C | H1N1 | HIV | HCV | Bacteria, rarely fungi or viruses | Bacteria, rarely fungi |
| Deaths/timeframe | 270.000/5 months | 1.500.000/year 2018 (230.000 children) | 290.000 to 650.000/year 2015 | 151.000 to 575.400 | 770.000/year 2018 | 399.000/year 2016 | 1 to 2 million | 100.000 to 140.000 |
| New symptomatic cases/year | n/a | 10 million (5.7 million men 3.2 million women 1.1 million children) | 3 to 5 million [ | 60.8 million | 1.7 million | 1.7 million | > 20 million | 1 to 1.4 million |
| Estimated prevalence | 3.9 million* | > 2 billion (5-15% lifetime risk of falling ill) | n/a | n/a | 37.9 million | 71 million | Several million | Several million |
| Geography | n/a | 44% South-East Asia 24% Africa 18% Western Pacific | n/a | n/a | >75% Africa | Worldwide prevalence ranging from 0.5% to 2.3%. | Worldwide prevalence ranging from 5% to >15% of hospitalized patients | n/a |
*Can be underestimated due to a lack of test and >90% asymptomatic individuals
**Variable data across studies
n/a.: not available